Watchlist Price Alert

Crinetics Pharmaceuticals... (CRNX)

NASDAQ: CRNX · Real-Time Price · USD

30.70

0.20 (0.66%)

At close: Jun 20, 2025, 10:08 AM

0.66% (1D)

Bid	22.07
Market Cap	2.88B
Revenue (ttm)	760K
Net Income (ttm)	-328.25M
EPS (ttm)	-3.8
PE Ratio (ttm)	-8.08
Forward PE	-6.51
Analyst	Buy

Ask	39.29
Volume	119,591
Avg. Volume (20D)	937,098
Open	30.61
Previous Close	30.50
Day's Range	30.23 - 30.86
52-Week Range	24.10 - 62.53
Beta	0.28

About CRNX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CRNX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CRNX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Crinetics Pharmaceuticals Inc. is scheduled to release its earnings on Aug 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

+1.26%

Crinetics Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription

10 months ago

-6.11%

Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results. Additionally, the company announced its CFO will be departing and Oppenheimer lowered its price target on the stock from $74 to $73.

News

1 month ago · seekingalpha.com

Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief...

1 month ago · zacks.com

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $0.93 per share a year ago.

2 months ago · seekingalpha.com

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

Crinetics Pharma's lead asset, Paltusotine, shows promising Phase 3 results for acromegaly, with a PDUFA date set for September 25, 2024. Paltusotine, an oral SST2 agonist, offers advantages over inje...